Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)

BACKGROUND: Androgen deprivation therapy (ADT) for prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonists can be improved. OBJECTIVE: To assess safety, the frequency and severity of hot flushes (HFs), bone health, and antitumor effects of high-dose estetrol (HDE4) when combined w...

Descripción completa

Detalles Bibliográficos
Autores principales: Coelingh Bennink, Herjan J.T., van Moorselaar, Jeroen A., Crawford, E. David, Roos, Erik P.M., Somford, Diederik M., Roeleveld, Ton A., de Haan, Tjard D., van Melick, Harm H.E., Reisman, Yacov, Zimmerman, Yvette, van Osta, Gonnie, Krijgh, Jan, Shore, Neal D., Saad, Fred, Schally, Andrew V., Debruyne, Frans M.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Prostate Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317802/
https://www.ncbi.nlm.nih.gov/pubmed/34337526
http://dx.doi.org/10.1016/j.euros.2021.04.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317802/
https://www.ncbi.nlm.nih.gov/pubmed/34337526
http://dx.doi.org/10.1016/j.euros.2021.04.005

Ejemplares similares